Novo Nordisk stock holds lower as 2026 outlook narrows
Published on 08/17/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (DK0062498333) is trading at 293.35 DKK on the Copenhagen exchange, down 0.46% on August 17, 2026, while the same session snapshot shows a 5-day change of -4.10% and a year-to-date move of -9.73%.
The stock is digesting a Reuters-linked August 17 report on GLP-1 demand and a pricing backdrop that still leaves analysts at a 313.70 DKK average target, or 6.45% above the last close in the same market snapshot.
Outlook stays under review
Second-quarter sales rose 3% in constant currency to 78.49 billion kroner, and adjusted sales increased 7%, according to the August 17 coverage of the company’s latest update. Novo Nordisk also narrowed its 2026 outlook to a 0% to 6% expected decline in adjusted sales and operating profit from a prior 4% to 12% range, a concrete improvement even though it still points to contraction.
That combination matters because it gives investors a cleaner lens on the gap between stronger reported sales and a still cautious full-year framework. The article also noted that injectable Wegovy sales were flat year over year in the second quarter, which helps explain why the shares have stayed under pressure despite the guidance reset.
Competition keeps rising
Competitive pressure from Eli Lilly remains part of the same story, and the market continues to weigh whether the obesity franchise can defend share as pricing, demand and pipeline execution evolve. A separate Reuters report on August 17 showed how GLP-1 drugs are reshaping adjacent consumer categories, underscoring how broad the commercial impact of Novo Nordisk products has become.
For investors, the key comparison is straightforward: 78.49 billion kroner of second-quarter sales and a 0% to 6% guidance band sit beside a share price that is still below the August 14 close and a market value of roughly $201.72 billion on a U.S. quote page. The numbers point to a stock that is being judged on execution, not on narrative alone.
Wegovy remains central
Wegovy remains the most visible product in the portfolio because it sits at the center of the company’s obesity franchise and the broader GLP-1 category. The latest reporting also highlighted oral and injectable semaglutide products as the commercial core behind Novo Nordisk’s diabetes and obesity business.
Stock and venue
On the latest U.S. quote snapshot, Novo Nordisk A/S traded at $45.31 at 4:00 p.m. ET on August 14, 2026, with a market cap of $201.72 billion and a P/E ratio of 11.47. The same market view showed an after-hours price of $45.49 and an ex-dividend date of August 17, 2026.
Company details
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NVO
Exchange: NYSE
Sector / Industry: Pharmaceuticals / Pharmaceuticals
Index membership: S&P 500
More on Wegovy
Wegovy is Novo Nordisk's best-known obesity medicine and the clearest read-through for the company’s GLP-1 momentum. The August 17 coverage tied that franchise to second-quarter sales growth, flat Wegovy sales in injections, and the revised 2026 outlook.
More on Novo Nordisk stock
Shares were last quoted at $45.31 on August 14, 2026, with after-hours trading at $45.49. On the Copenhagen quote snapshot, the stock stood at 293.35 DKK on August 17, 2026.
